


# Endometrial Cancer Prognostication Panel

Next Generation Sequencing based genomic profiling for molecular classification of endometrium cancer



ESGO–ESMO–ESTRO risk stratification model classifies endometrial cancer into four subgroups according to molecular profile.



## MedGenome Endometrial Cancer Prognostication Gene Panel

Genomic alterations in 32 endometrial cancer related genes are screened along with mutations in **POLE**, **TP53**, **MMR** genes using NGS

- Provides accurate diagnosis, prognosis and therapy selection for all stages of disease etiology including recurrent disease
- Provides information on genes which might be involved in germline origin of disease such as **BRCA1**, **BRCA2** and **MMR** pathway genes.
- Covers tumour agnostic biomarkers such **BRAF**, **RET**, **NTRK1**, **NTRK2** and **NTRK3** which have approved targeted therapies across all metastatic solid tumours.

Laboratory developed assay  
as per CAP guidelines

Sensitivity >98% and  
Specificity with 100%

Limit of detection:

- 5% VAF for SNV and InDels,
- >10 Spanning Reads for Fusions,
- >2.5-fold Change for CNV

## Benefits



Molecular subgrouping allows better prediction of prognosis.



Tailoring different treatment modalities such as surgery, pelvic radiotherapy, vaginal brachytherapy, chemotherapy and immunotherapy.\*

\*Crosbie, Emma J., et al. "Endometrial cancer." The Lancet 399.10333 (2022): 1412-1428.

## Test Details

Test Code	TAT	Test Name	Inclusions
MGM1434	21 Working Days	Endometrial Cancer - POLE gene sequencing	POLE by NGS
MGM3239	14 Working Days	Endometrial Cancer - Basic NGS Panel	POLE, TP53, MLH1, MSH2, MSH6, PMS2 by NGS
MGM3240	14 Working Days	Endometrial Cancer - Molecular Classification Panel	POLE by NGS + TP53 by IHC + dMMR by IHC
MGM2581	14 Working Days	Endometrial Cancer panel by NGS	As shown in the Gene List Below

Methodology: Next Generation Sequencing | Specimen Type: FFPE Tissue Block / Tissue in RNAlater

## Gene List (MGM2581)

GENES	SNVs/ InDels	FUSION	GENES	SNVs/ InDels	FUSION	GENES	SNVs/ InDels	FUSION
AKT1	Y	N	FGFR2	Y	Y	PIK3CA	Y	N
ARID1A	Y	N	FGFR3	Y	Y	PIK3R1	Y	N
BRCA1	Y	N	KRAS	Y	N	PMS2	Y	N
BRCA2	Y	N	MLH1	Y	N	POLD1	Y	N
BRAF	Y	N	MSH2	Y	N	POLE	Y	N
CHEK2	Y	N	MSH3	Y	N	PTEN	Y	N
CTNNB1	Y	N	MSH6	Y	N	RET	Y	Y
EPCAM	Y	N	MUTYH	Y	N	SMARCA4	Y	N
ERBB2	Y	N	NTRK1	Y	Y	STK11	Y	N
FBXW7	Y	N	NTRK2	Y	Y	TP53	Y	N
FGFR1	Y	Y	NTRK3	Y	Y			

\*Tumor Cellularity can not be determined for tissue in RNA later samples. VAF : Variant Allele Frequency

\*RNAlater solution will be provided by MedGenome

Talk to the Experts:

1800 296 9696  
[diagnostics@medgenome.com](mailto:diagnostics@medgenome.com)  
[www.medgenome.com](http://www.medgenome.com)

Scan to  
Follow us on  
LinkedIn

